VivoSeq
Oncology

Metastatic Colorectal Cancer

569

Pipeline Programs↗

188

Active Trials↗

165

Companies Involved↗

Metastatic Colorectal Cancer is a highly competitive landscape with 569 programs across 165 companies. The most active players are OncoMed Pharmaceuticals, Inc., Wondercel Biotech (ShenZhen), Cornerstone Pharmaceuticals. 15 therapies are approved with 86 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

97/100

Pipeline Velocity

67/100

Mech. Concentration

5/100

Completion Rate

74/100

Attrition Rate

16/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

O

OncoMed Pharmaceuticals, Inc.

3 programs

Phase 1W

Wondercel Biotech (ShenZhen)

2 programs

Phase 1C

Cornerstone Pharmaceuticals

2 programs

Phase 1A

Aduro Biotech, Inc.

2 programs

Phase 1C

Celyad Oncology SA

1 program

Phase 1O

Oncolytics Biotech

1 program

Phase 1

Pipeline

Programs by Phase

Analysis

Modality Breakdown

79%

Small molecule

517 of 657 classified programs — the dominant modality here.

21%ALL OTHERSMonoclonal antibody10216%Protein / enzyme142%Vaccine132%Cell therapy71%Antibody–drug conjugate3<1%RNA therapy1<1%

Small molecule leads; the ring shows all 657 classified programs, each share of the total. Modality classified for 99% of 699 pipeline programs.

Analysis

Trial Status

934

clinical trials

Completed445 · 48%
Unknown status142 · 15%
Terminated118 · 13%
Recruiting104 · 11%
Not yet recruiting43 · 5%
Active, not recruiting40 · 4%
Other42 · 4%

Clinical Trials

Trial Activity

934 trials

Bevacizumab Plus mFOLFOXIRI as First-line Treatment for Patients With Unresectable Metastatic Colorectal Cancer
Recruiting·—·Phase 3·NCT04230187·528 enrolled
Efficacy and Safety of Combined With Immunotherapy After Induction Therapy With Chemotherapy and Targeted Therapy in the First-line Treatment of Microsatellite Stable (MSS) Initially Unresectable Metastatic Colorectal Cancer
Recruiting·—·Phase 2·NCT06176885·36 enrolled
FOLFOXIRI Plus Bevacizumab With or Without Atezolizumab as 1st Line Treatment of pMMR and IS IC-High Metastatic Colorectal Cancer Patients.
Recruiting·GGruppo Oncologico del Nord-Ovest·Phase 3·NCT06733038·238 enrolled
Study of Pembrolizumab Treatment After CYAD-101 With FOLFOX Preconditioning in Metastatic Colorectal Cancer
Recruiting·CCelyad Oncology SA·Phase 1·NCT04991948·34 enrolled
Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal Cancers
Recruiting·—·Phase 2·NCT06425133·174 enrolled
Encorafenib + Cetuximab Beyond Progression in Combination With FOLFIRI in Patients With BRAF V600E Mutated Metastatic Colorectal Cancer Progressing on Encorafenib + Cetuximab.
Recruiting·FFondazione Policlinico Universitario Agostino Gemelli IRCCS·Phase 2·NCT06640166·25 enrolled
Sulfasalazine in Patients With Metastatic Colorectal Cancer
Recruiting·TTanta University·Phase 3·NCT06134388·50 enrolled
A Clinical Study on the Efficacy and Safety of Fruquintinib in Combination With PD-1 Monoclonal Antibody and Chidamide in Refractory MSS Metastatic Colorectal Cancer
Recruiting·TThe First Hospital of Jilin University·Phase 2·NCT06979908·46 enrolled
Efficacy and Safety of Tunlametinib Plus Vemurafenib in Patients With BRAF V600E-mutant Metastatic Colorectal Cancer
Recruiting·SShanghai Kechow Pharma, Inc.·Phase 3·NCT06008119·165 enrolled
Cetuximab and Envafolimab Plus mFOLFOXIRI as First-line Treatment for RAS/BRAF Wild-type, MSS, Unresectable Left-side Metastatic Colorectal Cancer
Recruiting·SSun Yat-sen University·Phase 2·NCT05959356·198 enrolled
Trifluridine/Tipiracil Plus Regorafenib vs Trifluridine/Tipiracil Plus Bevacizumab for Refractory Metastatic Colorectal Cancer
Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 3·NCT06992648·302 enrolled
Regorafenib Alone or in Combination With Hypofractionated/Low-dose Radiotherapy Plus Toripalimab for Metastatic Colorectal Cancer
Recruiting·FFudan University·Phase 2·NCT05963490·108 enrolled
DOSAGE Study: Upfront Dose-Reduced Chemotherapy in Older Patients with Metastatic Colorectal Cancer
Recruiting·LLeiden University Medical Center·Phase 3·NCT06275958·587 enrolled
Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer
Recruiting·RRutgers, The State University of New Jersey·Phase 2·NCT05806931·50 enrolled
Clinical Study of Fruquintinib Combined With Raltitrexed in the Treatment of Metastatic Colorectal Cancer
Recruiting·TThe First Affiliated Hospital of Nanchang University·Phase 4·NCT06118762·30 enrolled
Page 1 of 63

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)